Supportive therapy with megestrol acetate in myeloproliferative neoplasms
Authors:
J. Hubáček; E. Faber; K. Indrák
Authors place of work:
Hemato-onkologická klinika, LF UP a FN Olomouc
Published in the journal:
Transfuze Hematol. dnes,18, 2012, No. 4, p. 174-176.
Category:
Souhrnné práce, původní práce, kazuistiky
Summary
We present three cases of patients with myeloproliferative neoplasm that were because of anorexia and weight reduction given megestrol acetate to improve their alimentation and so their life quality. Clinically important reduction of splenomegaly and reduction or loss of transfusion dependence after administration of gestagen were observed as side effect in all patients. After discontinuation the spleen started to grow again, but administration of megestrol has led to its repeated diminution. This is the first description of the important „side effect“ of megestrol in patients with myeloproliferative neoplasms and prominent splenomegaly.
Key words:
splenomegaly, myeloproliferative neoplasm, megestrol acetate, transfusion dependence
Zdroje
1. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29 (6): 761-770.
2. Benghiat A, Cassidy SA. Megestrol acetate in treatment of advanced post-menopausal brest cancer. Eur J Surg Oncol 1986; 12 : 43-45.
3. Bonomi P, Pessis D, Bunting N, et al. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin Oncol 1985; 12(Suppl 1): 36-39.
4. Fjøsne HE, Jacobsen AB, Lundgren S. Adjutant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal brest cancer patients – long-term follow-up. J Canc Surg 2008; 34 : 6-12.
5. Indrák K. Chronické myeloproliferativní stavy. In: Indrák K. a kol. Hematologie. 1. vyd. Praha/Kroměříž, Triton, 2006; 149-155.
6. Gregory EJ, Cohen SC. Megestrol acetate therapy for advanced breast cancer. J Clin Oncol 1985; 3 : 155-160.
7. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Supp Care Canc 2010; 18 : 951-956.
8. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115(15): 3109-3117.
9. Von Roenn JH. Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia. Oncol 1994; 51(Suppl. 1): 19-24.
Štítky
Hematologie a transfuzní lékařství Interní lékařství OnkologieČlánek vyšel v časopise
Transfuze a hematologie dnes
2012 Číslo 4
Nejčtenější v tomto čísle
- První zkušenosti jednoho centra s použitím přípravku Octaplas® v léčbě pacientky s vrozenou formou trombotické trombocytopenické purpury
- Pokyny autorům Transfuze a hematologie dnes
- Zajištění operačních výkonů u pacientů s von Willebrandovou chorobou preparátem Wilate® – první klinické zkušenosti jednoho centra v ČR
- Podpůrná terapie megestrol acetátem u myeloproliferativních neoplazií